4.6 Review

Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options

期刊

BRITISH JOURNAL OF OPHTHALMOLOGY
卷 101, 期 1, 页码 25-30

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bjophthalmol-2016-308823

关键词

-

资金

  1. National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust
  2. UCL Institute of Ophthalmology
  3. Fight For Sight (UK)
  4. Macular Society (UK)
  5. Moorfields Eye Hospital Special Trustees
  6. Moorfields Eye Charity
  7. Wellcome Trust [099173/Z/12/Z]
  8. Foundation Fighting Blindness (USA)
  9. Retinitis Pigmentosa Fighting Blindness
  10. FFB Career Development Award
  11. Austrian Science Fund (FWF) [J 3383-B23]
  12. Foundation Fighting Blindness Clinical Research Institute (USA)
  13. FFB Clinical Research Fellowship Program Award
  14. Ministry of Education, Culture, Sports, Science and Technology (Japan)
  15. National Hospital Organization Network Research Fund (Japan)

向作者/读者索取更多资源

Stargardt disease (STGD1; MIM 248200) is the most prevalent inherited macular dystrophy and is associated with disease-causing sequence variants in the gene ABCA4. Significant advances have been made over the last 10 years in our understanding of both the clinical and molecular features of STGD1, and also the underlying pathophysiology, which has culminated in ongoing and planned human clinical trials of novel therapies. The aims of this review are to describe the detailed phenotypic and genotypic characteristics of the disease, conventional and novel imaging findings, current knowledge of animal models and pathogenesis, and the multiple avenues of intervention being explored.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据